Bristol-Myers Squibb Co (BMY) Q1 2020 earnings call dated May. 07, 2020 Corporate Participants: Timothy Power -- Vice President, Investor Relations Giovanni Caforio -- Chairman of
Bristol-Myers Squibb Co.
-(BMY)
XNYS:BMY
Visual Representation of Bristol-Myers Squibb Company (BMY) Q1 2020 earnings
Bristol-Myers Squibb Company (NYSE: BMY) reported first-quarter 2020 financial results before the regular trading hours on Thursday. The results were better than
Bristol-Myers Squibb (BMY) slips to a loss in Q4 but beats estimates
Bristol-Myers Squibb Company (NYSE: BMY) slipped to a loss in the fourth quarter of 2019 from a profit last year, due to
Bristol-Myers Squib (BMY) set to report Q4 earnings – what is in the offing?
After closing the high-value acquisition of Celgene a few months ago, Bristol-Myers Squib (NYSE: BMY) will be publishing its fourth-quarter results on
Top five merger and acquisition deals of 2019
Every year has its share of mergers and acquisitions and 2019 was no different. Several prominent companies announced their decision to team
Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales
Driven by the strong sales of leading products, earnings of Bristol-Myers Squibb (NYSE: BMY) increased in the third quarter and exceeded the
Bristol-Myers (BMY) Q3 earnings preview: New indications, pipeline to bolster recovery
Bristol-Myers Squibb (NYSE: BMY) will be publishing its September-quarter earnings Thursday before the opening bell. The bio-pharmaceutical company is expected to earn
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),
M&A alert: AbbVie agrees to acquire Allergan for $63 billion
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE:
Bristol-Myers lets go of psoriasis drug to save Celgene merger; stock falls
The planned merger between pharmaceutical firms Bristol-Myers Squibb Company (NYSE: BMY) and Celgene (CELG) - touted as a landmark deal in the
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
10 biggest US mergers & acquisitions announced so far in 2019
We are almost half-way into this year and the M&A market has not disappointed. We have seen a few massive deals so
Bristol-Myers Squibb tops Q1 estimates, gets shareholder approval for Celgene acquisition
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported better-than-expected first-quarter 2019 results, sending its shares up over 1% during pre-market trading.
Celgene stock jumps after advisory firm backs merger with Bristol-Myers Squibb
The planned acquisition of Celgene (CELG) by rival drugmaker Bristol-Myers Squibb (BMY) got a new lease of life this week after proxy
Celgene stock takes a dive after major Bristol-Myers stakeholder opposes merger deal
It's was a wild day for big pharma after Celgene Corp (CELG) slid at least 8% on early Thursday trade after one
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
Earnings: Array BioPharma delivers strong Q2 results, investors cheer
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million
Celgene posts upbeat Q4 results, guidance
Celgene Corp. (CELG) swung to a profit in the fourth quarter from a loss last year, helped by lower research and development
Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect
Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results